secukinumab + tofacitinib

Secukinumab + tofacitinib is a combination of two immunomodulatory drugs used off-label in certain cases for the management of immune-mediated inflammatory diseases, such as psoriatic arthritis and ankylosing spondylitis. Secukinumab is a fully human monoclonal antibody that selectively binds to and inhibits interleukin-17A (IL-17A), thereby blocking its pro-inflammatory effects. Tofacitinib is an oral small molecule inhibitor of Janus kinases (JAKs), primarily JAK1 and JAK3, which are key mediators in cytokine signaling pathways involved in inflammation. This combination targets different but complementary pathways within the immune system, potentially offering enhanced efficacy for patients with refractory disease who have not responded adequately to monotherapy or other standard treatments[2][3][8].